News|Articles|November 18, 2026

Nelkarmi gives ALK-positive lung cancer patients a new option after first-line therapy stops working

Listen
0:00 / 0:00

Key Takeaways

  • Accelerated approval spans two prior-treatment cohorts: alectinib-only exposure and more heavily pretreated patients previously receiving multiple ALK TKIs plus platinum-based chemotherapy.
  • ALKOVE-1 demonstrated durable systemic responses, with 76% of responders maintaining response at six months post-alectinib and 51% maintaining response at 12 months in later lines.
SHOW MORE

The FDA granted accelerated approval to GSK's Nelkarmi for previously treated ALK-positive NSCLC, the company's second lung cancer approval this year.

The FDA recently granted accelerated approval to Nelkarmi (neladalkib), a once-daily oral pill, for adults with locally advanced or metastatic ALK-positive non-small cell lung cancer (NSCLC) whose disease has already been treated with an ALK-targeted drug, GSK announced in a news release.

The approval covers two groups of patients: those whose only prior ALK tyrosine kinase inhibitor (TKI) was Alecensa (alectinib) and those who have received two or more ALK TKIs plus platinum-based chemotherapy. The FDA acted ahead of its Nov. 27 target date. Nelkarmi had previously received Breakthrough Therapy and Orphan Drug designations from the agency.

GSK added Nelkarmi to its pipeline through its $10.6 billion acquisition of Nuvalent earlier this year. The approval follows the FDA's July decision on Jideytro (zidesamtinib), another Nuvalent drug, for previously treated ROS1-positive NSCLC, according to GSK's third-quarter filing with the Securities and Exchange Commission.

What the ALKOVE-1 trial showed

The FDA based its decision on tumor response rates and how long those responses lasted in ALKOVE-1, a single-arm phase 1/2 trial. The initial analysis included 222 patients with previously treated NSCLC.

In the 67 patients whose only prior ALK drug was Alecensa, 49% had their tumors shrink. Out of those who responded, 76% were still responding at six months and 52% were still responding at a year. Results were lower but still meaningful in the 155 more heavily pretreated patients: 32% responded, and 51% of responders were still responding at 12 months.

Brain metastases are a common concern in this disease. Among patients with measurable tumors in the brain, 55% (11 of 20) in the Alecensa-only group saw those tumors shrink, as did 26% (14 of 53) in the more heavily pretreated group.

Safety data came from a pooled group of 700 patients. The most common side effects were liver toxicity (56%), muscle and bone pain (33%), constipation (28%), changes in taste (24%), nerve pain or numbness (23%), swelling (21%) and fatigue (21%). Serious side effects occurred in 30% of patients, and 5% stopped treatment because of side effects, most often liver problems. The label carries warnings for liver, kidney and eye toxicity, elevated creatine phosphokinase and harm to a developing fetus.

Because this is an accelerated approval, continued approval may depend on a confirmatory trial showing clinical benefit.

Why ALK-positive lung cancer is a long-term treatment challenge

Lung cancer remains the leading cause of cancer death in the U.S. The American Cancer Society estimates 229,410 new cases and 124,990 deaths in 2026. ALK-positive disease is a small slice of that total. A real-world analysis of nearly 20,000 U.S. patients with advanced NSCLC, published in Oncotarget, found ALK rearrangements in 2.6% of patients overall but in 21.6% of those ages 18 to 39.

That younger profile means many patients cycle through several targeted therapies over many years, which makes durability and tolerability central questions for clinicians and health plans alike.

“ALK-positive patients are often younger and can remain on treatment for years, making effective and tolerable new treatment options especially important,” Tony Wood, chief scientific officer at GSK, said in the news release.

Alice Shaw, M.D., Ph.D., an ALKOVE-1 investigator and chair of the department of medical oncology at Dana-Farber Cancer Institute, said in the release that the field is moving closer to managing the disease as a chronic condition “but balancing disease control and long-term tolerability remains a significant challenge.”

What's next: ALKAZAR tests Nelkarmi against Alecensa

GSK is also studying Nelkarmi as a first treatment. ALKAZAR is a phase 3 trial that plans to randomly assign about 450 patients with previously untreated ALK-positive NSCLC to Nelkarmi or Alecensa, the current standard. Its primary goal is to show that Nelkarmi keeps the disease from progressing longer, according to the trial's ClinicalTrials.gov listing. The trial is still recruiting, with primary completion estimated for 2029. Nelkarmi is also being evaluated in other solid tumors.

“As patients move through multiple therapies over the course of their disease, they need options that balance durable disease control with the ability to tolerate and remain on treatment and maintain quality of life,” Kirk Smith, president of the patient advocacy group ALK Positive, said in the release.


Related to this article